Drug intelligence / Profile preview

lactobacillus paracasei subsp. paracasei + lactobacillus rhamnosus + arginine

Development stage: Unknown
Lead developer: GenMont Biotech
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Peptides, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This combination consists of two probiotic bacterial strains, *Lactobacillus paracasei* subsp. *paracasei* and *Lactobacillus rhamnosus*, along with the amino acid L-arginine. It is primarily investigated and used as a dietary supplement for oral health, specifically for the prevention of dental caries (cavities). The mechanism involves a synergistic effect where the probiotics compete with cariogenic bacteria like *Streptococcus mutans* for colonization and nutrients, while arginine serves as a substrate for the arginine deiminase pathway (ADS) in beneficial oral bacteria (such as *Streptococcus sanguinis*). The metabolism of arginine produces ammonia, which helps neutralize the acidic environment in the oral biofilm, thereby raising the pH and inhibiting the demineralization of tooth enamel. This dual approach aims to shift the oral microbiome from a dysbiotic, acidogenic state to a more balanced, health-associated state.

Other names: probiotic-arginine combinationL. paracasei + L. rhamnosus + arginine

Targets

ADI (Arginine deiminase)

Beyond the preview

Go deeper on lactobacillus paracasei subsp. paracasei + lactobacillus rhamnosus + arginine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus paracasei subsp. paracasei + lactobacillus rhamnosus + arginine.

Explore the full profile